Anilinopyrimidines as haematopoietic progenitor kinase 1 (HPK1) inhibitors
US11180482B2 · kind B2 · utility
0Cited by
0References
12Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 29, 2017 |
| Grant date | Nov 23, 2021 |
| Priority date | — |
| Expiry date | Nov 29, 2037 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to HPK1 inhibitors useful in the treatment of cancers, and other serine-threonine kinase mediated diseases, having the Formula: where A, R1, R2, R3, R4, R5, R6, R16, R17, X1, X2, X3, X4, m, and n are described herein.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.